EMA Authorised: Dasatinib Accord Healthcare (Dasatinib monohydrate) — Accord Healthcare S.L.U.

View source ↗

Summary

EMA authorised Accord Healthcare's dasatinib monohydrate product (Dasatinib Accord Healthcare) for precursor B-cell lymphoblastic leukemia/lymphoma and chronic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Precursor B-cell Lymphoblastic Leukemia Lymphoma

Drugs mentioned

• Dasatinib Accord Healthcare (dasatinib monohydrate)

Snippet

Status: Authorised. Therapeutic area: Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Myelogenous, Chronic, BCR-ABL Positive. MAH: Accord Healthcare S.L.U.. Decision date: 04/02/2026